Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Axitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 7/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Axitinib SCHEMBL29384419 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL843204 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29349703 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL2826667 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29387511 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248175 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248178 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL23044964 | 0.94 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29459456 | 0.94 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| SCHEMBL24503457 | 0.91 | KDR (0.84) | KDRFGFR1FLT1FLT4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| CN-118286440-A | Combination of PD-1 antagonists and VEGFR inhibitors for the treatment of cancer | 辉瑞大药厂 | 2024-07-05 | — | — | CN | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| EP-4249063-A2 | CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS | Pfizer Products Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| EP-2134702-B2 | CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS | PFIZER PROD INC (US) | 2023-08-30 | — | — | EP | claimed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-3252047-B1 | CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS | PFIZER PROD INC (US) | 2022-05-11 | — | — | EP | claimed |
| EP-3971209-A1 | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER | Pfizer Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| CN-107750166-B | PD-L1 antagonist combination therapy | 默克专利股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-1949902-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1885338-A1 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN AMORPHOUS FORM OF A VEGF-R INHIBITOR | Pfizer, Inc. (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1819696-A1 | POLYMORPHIC FORMS OF 6-2-(METHYLCARBAMOYL)PHENYSULFANYL|-3-E-2-(PYRIDIN-2-YL)ETHENYL INDAZOLE | Pfizer, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| WO-2006123223-A1 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN AMORPHOUS FORM OF A VEGF-R INHIBITOR | PFIZER INC. (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| WO-2006048751-A1 | POLYMORPHIC FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE | PFIZER INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060094763-A1 | Polymorphic forms of 6-[2-(methylcarbomoyl) phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole | AGOURON PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885FLT1 3/4885FLT4 1/4885 |
| US-20060094763-A1 | Polymorphic forms of 6-[2-(methylcarbomoyl) phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole | BRCA1, CSNK1G3, PRKACB | KDR 3044/4885FLT1 3957/4885FLT4 3174/4885 |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | KDR 3850/4885FLT1 3446/4885FLT4 3252/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDR 277/4885FLT1 326/4885FLT4 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.